Store STELFONTA vials refrigerated at 2°C to 8°C (35°F to 46°F).
Do not freeze.
Keep the vial in the carton at all times to protect the vial from light.
For single use only.
Dispose of any unused product in accordance with disposal for routine medical waste.
STELFONTA is supplied as a sterile, colorless liquid in a 5 mL clear, single-use glass vial containing 2 mL of STELFONTA at a concentration of 1 mg/mL tigilanol tiglate in sterile water for injection.
1. Veterinary Cooperative Oncology Group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biologic antineoplastic therapy in dogs and cats v1.1. Vet Compar Oncol. 20 Jul 2011.
2. Eisenhauer EA, Therase P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1), Eur J Cancer. 2009; 45(2):228-247.
3. Lynch S, Savary-Bataille K, Leeuw B, Argyle DJ. Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. Vet Compar Oncol. 2011; 9 (3):172-82.
Approved by FDA under NADA # 141-541
STELFONTA® is a registered trademark of QBiotics Group Limited.
Distributed by Virbac AH, Inc.
P.O Box 162059,
Fort Worth, Texas 76161.
Version date: August 2020
| STELFONTA 1 MG/ML |
tigilanol tiglate injection solution
|Labeler — Virbac AH Inc (131568396)|
|Registrant — QBiotics Group LTD (744550801)|
Revised: 02/2021 Virbac AH Inc
VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.